Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

This is a randomized, double-blind, placebo-controlled, multi-centre trial. A total of 300 CHR subjects will be identified in the course of face-to-face interviews using the Structured Interview for Prodromal Syndromes. All participants will be randomly allocated to SFN group (n = 150) or placebo group (n = 150). The study duration includes an intervention for 52 consecutive weeks, and additional 1-year follow-up. The primary outcome is 2-year conversion rate of psychosis. Secondary outcomes include 1-year conversion rate of psychosis, the severity and duration of prodromal symptoms, predictive risk of psychosis conversion, neurocognitive functioning and peripheral blood biomarkers of inflammation, oxidative stress and metabolism. Safety monitoring will be performed using scales for side effect, serious adverse events recording, and laboratory tests.

NCT Number	NCT03932136
Lead Sponsor	Shanghai Jiao Tong University School of Medicine Collaborators: Shanghai Xuhui District Mental Health Center, Shanghai Pudong New Area Nanhui Mental Health Center, Suzhou Psychiatric Hospital, Second Xiangya Hospital of Central South University, Guangzhou Psychiatric Hospital, Shenzhen Fushan Biotech Co., Ltd., Tianjin Anding Hospital, The First Affiliated Hospital of Zhengzhou University, Shenzhen Kangning Hospital
Conditions	Clinical High Risk Syndrome of Psychosis
Enrollment	300 participants
Start Date	2019-07-14
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-03